Phase 2/3 clinical study of HP-3150 in patients with cancer pain.

Trial Profile

Phase 2/3 clinical study of HP-3150 in patients with cancer pain.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs HP 3150 (Primary)
  • Indications Cancer pain
  • Focus Registrational; Therapeutic Use
  • Sponsors Hisamitsu Pharmaceutical
  • Most Recent Events

    • 30 Nov 2016 Status changed from recruiting to completed.
    • 29 Aug 2016 According to a Hisamitsu Pharmaceuticals media release, based on an investigation of the results of this trial company will decide whether to continue or stop the development.
    • 01 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top